Free Trial
NASDAQ:NCNA

NuCana 8/15/2024 Earnings Report

NuCana logo
$0.08 +0.03 (+50.36%)
As of 12:38 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

NuCana EPS Results

Actual EPS
-$3.79
Consensus EPS
-$3.55
Beat/Miss
Missed by -$0.24
One Year Ago EPS
N/A

NuCana Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NuCana Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

NuCana's next earnings date is estimated for Wednesday, August 13, 2025, based on past reporting schedules.

Conference Call Resources

NuCana Earnings Headlines

NuCana PLC ADR Stock Grades | NCNA - Barron's
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
See More NuCana Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NuCana? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NuCana and other key companies, straight to your email.

About NuCana

NuCana (NASDAQ:NCNA) plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

View NuCana Profile

More Earnings Resources from MarketBeat